This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETF Strategies for the Midterm Elections
by Sweta Killa
Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.
ETFs Buoy on Booming Q2 Corporate Profits: 5 Best Charts
by Sweta Killa
We have highlighted five ETFs and their performance chart since Jul 13 that buoyed on robust earnings results.
Health Care ETFs Outperforming: Will the Rally Last?
by Sanghamitra Saha
Health care ETFs are defensive ones, which helped those to shine amid market doldrums.
Q2 Earnings Drive Pharma ETFs Higher
by Sweta Killa
The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.
5 Best-Performing Sector ETFs of July
by Sweta Killa
We have highlighted sector ETFs that witnessed handsome gains last month and could be better plays in the months ahead should the trends prevail.
What Lies in Store for Pharma ETFs?
by Zacks Equity Research
Pharma stocks have done well this year; what lies ahead?
What Lies Ahead for Pharma ETFs in Second Half 2017
by Zacks Equity Research
We discuss some of the factors that could contribute to a sustained recovery in the sector.
Republicans Present Healthcare Bill: Top 5 Gainers
by Tirthankar Chakraborty
Healthcare stocks posted record highs, with hospitals and insurers climbing after Senate Republicans released a draft bill to replace Obamacare.
The Zacks Analyst Blog Highlights: HCA Holdings, Molina Healthcare, SPDR S&P Pharmaceuticals ETF, BioShares Biotechnology Products Fund and The Health Care Select Sector SPDR Fund
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HCA Holdings, Molina Healthcare, SPDR S&P Pharmaceuticals ETF, BioShares Biotechnology Products Fund and The Health Care Select Sector SPDR Fund
Should You Buy Pharma ETFs Now?
by Zacks Equity Research
After a challenging 2016, are Pharma ETFs poised to rebound this year?
What Lies Ahead for Pharma ETFs?
by Zacks Equity Research
Pharma ETFs have sold off after Trump's comments; can they rebound?
Will a Clinton Presidency Spell Doom for Pharma ETFs?
by Zacks Equity Research
Ongoing drug pricing controversy continues to weigh on the industry but there are several reasons to take a look at the beaten down ETFs.